Adriana Matutino

5PUBLICATIONS
9CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Jul 13, 2024
Peripheral blood immune parameters, response, and adverse events after neoadjuvant chemotherapy plus durvalumab in early-stage triple-negative breast cancer.

Julia Foldi, Kim R M Blenman, Michal Marczyk

|Nov 16, 2023
Clinical Predictors of Survival in Patients With BRAFV600-Mutated Metastatic Melanoma Treated With Combined BRAF and MEK Inhibitors After Immune Checkpoint Inhibitors.

Adriana M Kahn, Curtis J Perry, Katrina Etts

|Sep 28, 2023
Treatment efficacy score: a better surrogate for arm-level survival differences in neoadjuvant breast cancer trials?

Rachel Jaber Chehayeb, Adriana Kahn, Lajos Pusztai

|Jul 29, 2022
Clinical Outcomes and Immune Markers by Race in a Phase I/II Clinical Trial of Durvalumab Concomitant with Neoadjuvant Chemotherapy in Early-Stage TNBC.

Julia Foldi, Adriana Kahn, Andrea Silber

|Jan 09, 2019
CDK4/6 inhibitors in breast cancer: beyond hormone receptor-positive HER2-negative disease.

Adriana Matutino, Carla Amaro, Sunil Verma

Pageof 1

Frequent Collaborators

3 joint publications

Lajos Pusztai

2 joint publications

Julia Foldi

1 joint publications

Andrea Silber

1 joint publications

Kim Blenman